+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the drug sarilumab in children and adolescents aged 1 to 17 years with Systemic Juvenile Idiopathic Arthritis sJIA. The study aims to describe how sarilumab behaves in the body pharmacokinetics, its effects pharmacodynamics, efficacy, and long-term safety in this population to determine an appropriate dose and treatment regimen. This is a Phase 2 open-label trial sponsored by Sanofi. Participants will receive one of two ascending doses or an additional intermediate dose of sarilumab by subcutaneous injection based on body weight. The selected dose will be administered once identified. Treatment begins with a 12-week core phase followed by a 144-week extension phase during which sarilumab continues to be given. After treatment, there is a 6-week post-treatment follow-up. Throughout the 166-week total study duration, participants will be monitored with various assessments including blood tests to measure drug levels and disease activity, evaluations of adverse events, and questionnaires to assess well-being and symptoms. Measurements like juvenile arthritis response rates and disease activity scores are tracked during both the core and extension phases. Safety, including injection site reactions and changes in glucocorticoid use, is also followed closely.

Age: 1Year - 17YearsAll GendersPhase 2
40 locations
O

Actively Recruiting

Researchers are studying the safety, tolerability, how the body processes, and potential disease-modifying effects of a drug called BMS-986528 in adults with refractory, difficult-to-treat rheumatoid arthritis RA. This early-phase trial aims to gather initial data on the drugs impact in this group of patients. The study is sponsored by Bristol-Myers Squibb and focuses on participants aged 18 to 65 with this challenging form of RA. Participants receive specified doses of BMS-986528 on certain days during the trial. The study includes multiple experimental cohorts, each receiving the drug under close monitoring. Throughout the treatment period, various measurements are taken to assess how the drug behaves in the body, including concentrations and clearance, as well as its effects on immune cells and antibody levels. During the study, participants are regularly assessed for any treatment-emergent side effects and serious adverse events up to week 54. Researchers also evaluate changes in disease activity scores and immune system markers. These evaluations involve blood tests and clinical assessments to monitor safety and potential benefits. The entire participation period extends up to approximately 54 weeks, allowing for comprehensive observation.

Age: 18Years - 65YearsAll GendersPhase 1Phase 2
39 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.

Age: 18Years +All GendersPhase 2
147 locations
O

Actively Recruiting

Researchers are evaluating the levels of plasma bimekizumab after subcutaneous administration in children aged 2 to under 18 years with active juvenile idiopathic arthritis subtypes, specifically enthesitis-related arthritis including juvenile-onset ankylosing spondylitis and juvenile psoriatic arthritis. This Phase 3 open-label trial aims to understand the pharmacokinetics and safety of bimekizumab in this pediatric population. Participants will receive weight-based doses of bimekizumab at scheduled times. The study is a single-arm design where all participants receive the investigational drug. The initial treatment period lasts up to 16 weeks, during which plasma concentrations of bimekizumab are monitored closely. Following this, there is a safety follow-up period lasting up to 141 weeks to track treatment-emergent adverse events and other safety parameters. Throughout the study, participants will undergo various assessments including vital signs, blood tests for biochemistry and hematology, growth measurements, and evaluations for injection site pain. Disease activity and response are measured using standardized pediatric arthritis scores. Researchers will also monitor for antibodies against bimekizumab and record any serious or specific safety events. The total participation may extend over several years to ensure long-term safety and treatment effects are observed.

Age: 2Years - 18YearsAll GendersPhase 3
23 locations
E

Actively Recruiting

This research aims to evaluate how safe and effective upadacitinib is in treating children and adolescents aged 1 to under 18 years with active systemic juvenile idiopathic arthritis sJIA, a severe form of juvenile arthritis that can affect joints and other organs like the liver and heart. The study includes a comparison group receiving tocilizumab, another treatment option, to assess changes in disease activity and adverse events. sJIA is a lifelong condition that can be challenging to manage, making this study important for improving treatment options. Participants are assigned to one of two groups Cohort 1 receives either upadacitinib or tocilizumab, while Cohort 2 receives upadacitinib alone. Upadacitinib is given as oral tablets once daily or oral solution twice daily, and tocilizumab is administered by subcutaneous injection or intravenous infusion following local guidelines. Treatment lasts for 52 weeks, followed by a 30-day safety follow-up period. The study involves about 90 participants across approximately 45 sites worldwide. During the study, participants will attend regular visits or calls at hospitals or clinics where medical assessments will be performed to monitor treatment effects and side effects. Researchers will collect information through questionnaires and clinical evaluations, including measuring the number of active joints, disease activity scores, and inflammation markers. The main outcomes focus on the percentage of participants showing improvement by week 12 and recording any adverse events up to week 52, with ongoing safety monitoring throughout the study.

Age: 1Year - 17YearsAll GendersPhase 3
45 locations